In spite of these scientific advances, clinical determination of steatohepatitis continues to rely on liver histology. Biopsy evaluation continues to play a central role in clinical trials as well.

For the first time, the European Medicines Agency has recognized AI software for the diagnosis of fatty liver hepatitis as ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder influenced by multiple genes, but their ...

PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted full qualification for ...

AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...

The findings from the new study in The American Journal of Pathology ... progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver ...

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic fatty liver diseases (NAFLD) into more severe forms of liver disease by ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a ... related to the specific lesions in the pathology of NASH, including the challenges of pediatric ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses ... A key factor in the pathology of MASH is the disruption of endoplasmic reticulum (ER) homeostasis.